Answers are grounded in this paper and cite their sources.
The tailor-made DOTA-conjugated PSMA inhibitor PSMA-617 presented here is sustainably refined and advanced with respect to its tumor-targeting and pharmacokinetic properties by systematic chemical modification of the linker region. Therefore, this radiotracer is suitable for a first-in-human theranostic application and may help to improve the clinical management of prostate cancer in the future.
No takes yet. Share an insight, caveat, or question.
Benešová et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: